http://www.advfn.com/nasdaq/rss.asp?symbol=SHPGY Shire Company Newsfeed en Tue, 10 Jul 2012 04:08:08 EDT Tue, 10 Jul 2012 04:08:08 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=53345161&headline=correction-to-shires-generic-adderall-xr-approval-story-on-june http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=53345161&headline=correction-to-shires-generic-adderall-xr-approval-story-on-june <div class='newsbody'><p> "Shire Sinks On Generic Adderall XR Approval But Rebound Seen" at 1250 GMT on June 25 incorrectly said Watson Pharmaceuticals had already bought Actavis in the second paragraph. </p> <p> Watson is still in the process of buying Actavis. </p> </div> Tue, 10 Jul 2012 04:08:08 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52988653&headline=fins-why-selling-drugs-will-never-be-the-same http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52988653&headline=fins-why-selling-drugs-will-never-be-the-same <div class='newsbody'><pre> By Beecher Tuttle </pre> <p> Ten years ago, the pharmaceutical representative was the rock star of the traveling sales world. A healthy economy, loose regulations on entertaining doctors and a steady stream of patent-protected "wonder pills" helped to open the door to almost... Tue, 03 Jul 2012 11:03:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52885124&headline=adr-report-shares-end-lower-as-investors-look-warily-to-european http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52885124&headline=adr-report-shares-end-lower-as-investors-look-warily-to-european <div class='newsbody'><pre> By Mia Lamar </pre> <p> International companies trading in New York closed lower Monday as investors looked to a European Union summit later this week with little enthusiasm. </p> <p> The Bank of New York index of ADRs fell 2.1% to 114.06 as financial stocks sold off. Spain's... Mon, 25 Jun 2012 17:26:20 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52878549&headline=shire-sinks-on-generic-adderall-xr-approval-but-rebound-seen http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52878549&headline=shire-sinks-on-generic-adderall-xr-approval-but-rebound-seen <div class='newsbody'><p> --Shire rival cleared to market Adderall XR generic </p> <p> --Shares sink more than 10% </p> <p> --Shire says expects to remain competitive in Adderall XR market </p> <pre> By Sten Stovall </pre> <p> LONDON--Shire PLC (SHP.LN), usually a darling of investors, had a rare bad... Mon, 25 Jun 2012 09:21:18 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52874655&headline=london-markets-shire-leads-ftse-100-lower-banks-miners-off http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52874655&headline=london-markets-shire-leads-ftse-100-lower-banks-miners-off <div class='newsbody'><p> By Sara Sjolin, MarketWatch </p> <p> LONDON (MarketWatch) -- Shire PLC led U.K. shares lower on Monday after a rival was cleared to market a generic version of one of Shire's drugs, while banks and miners declined ahead of euro-zone events later in the week. </p> <p> The FTSE... Mon, 25 Jun 2012 04:50:34 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52872963&headline=shire-expects-to-deliver-good-earnings-growth-for-2012 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52872963&headline=shire-expects-to-deliver-good-earnings-growth-for-2012 <div class='newsbody'><p> LONDON--Biopharmaceutical company Shire PLC (SHP.LN) Monday said expects to deliver good earnings growth for the full year 2012, and added that the U.S. Food and Drug Administration (FDA) has approved the abbreviated new drug applications for generic Adderall XR filed by Actavis... Mon, 25 Jun 2012 02:40:26 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52861958&headline=ema-recommends-against-marketing-authorization-to-pfizer-and http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52861958&headline=ema-recommends-against-marketing-authorization-to-pfizer-and <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> The European Medicines Agency has recommended against marketing authorization for Pfizer Inc. (PFE) and Protalix BioTherapeutics Inc. (PLX) for their Gaucher disease treatment, taliglucerase alfa. </p> <p> Protalix's shares were down 12% premarket... Fri, 22 Jun 2012 09:50:54 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52723145&headline=protalix-gets-25-million-milestone-payment-for-rare-disease http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52723145&headline=protalix-gets-25-million-milestone-payment-for-rare-disease <div class='newsbody'><pre> By Kristin Jones </pre> <p> Protalix BioTherapeutics Inc. (PLX) has received a $25 million milestone payment from Pfizer Inc. (PFE) after the U.S. Food and Drug Administration approved its new drug for the treatment of Gaucher disease. </p> <p> On May 1, U.S. regulators approved... Mon, 11 Jun 2012 08:29:40 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52238869&headline=correct-fda-approves-protalix-pfizer-drug-to-treat-gaucher http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52238869&headline=correct-fda-approves-protalix-pfizer-drug-to-treat-gaucher <div class='newsbody'><p> ("FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease," at 4:36 p.m. EDT, misstated the type of patients in the first paragraph. The correct version follows:) </p> <pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- The Food and... Tue, 01 May 2012 17:37:05 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52238389&headline=fda-approves-protalix-pfizer-drug-to-treat-gaucher-disease http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52238389&headline=fda-approves-protalix-pfizer-drug-to-treat-gaucher-disease <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- The Food and Drug Administration Tuesday approved a new treatment developed by Protalix Bio Therapeutics Inc. (PLX, PLX.TV) for children and adults with a type of Gaucher disease, a rare... Tue, 01 May 2012 17:07:24 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52231931&headline=supernus-pharmaceuticals-ipo-rises-after-cutting-price-range http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52231931&headline=supernus-pharmaceuticals-ipo-rises-after-cutting-price-range <div class='newsbody'><pre> By Lynn Cowan Of DOW JONES NEWSWIRES </pre> <p> Supernus Pharmaceuticals Inc. (SUPN) made early stock gains on Tuesday, its first day as a publicly traded company, after cutting its price steeply. </p> <p> The company's stock opened at $6.50 a share on the Nasdaq, up 30% from... Tue, 01 May 2012 11:18:21 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52187457&headline=pharma-m-a-surge-spurred-by-necessity-and-opportunity http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52187457&headline=pharma-m-a-surge-spurred-by-necessity-and-opportunity <div class='newsbody'><p> By Sten Stovall </p> <p> Of DOW JONES NEWSWIRES </p> <p> LONDON -(Dow Jones)- The sudden willingness of European drug companies to launch hostile takeover bids -- underscored by numerous bids this month -- underlines the depth of the sector's problems and its need to find new... Fri, 27 Apr 2012 10:54:37 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52163211&headline=correct-shire-expects-good-earnings-momentum-as-profit-rises http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52163211&headline=correct-shire-expects-good-earnings-momentum-as-profit-rises <div class='newsbody'><p> ("Shire Expects Good Earnings Momentum As Profit Rises," at 1154 GMT, omitted the product sales figure in the second paragraph. The correct version follows:) </p> <pre> By Simon Varcoe Of DOW JONES NEWSWIRES </pre> <p> LONDON -(Dow Jones)- U.K. drug company Shire PLC (SHP.LN... Thu, 26 Apr 2012 08:32:17 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52162661&headline=shire-expects-good-earnings-momentum-as-profit-rises http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52162661&headline=shire-expects-good-earnings-momentum-as-profit-rises <div class='newsbody'><pre> By Simon Varcoe Of DOW JONES NEWSWIRES </pre> <p> LONDON -(Dow Jones)- U.K. drug company Shire PLC (SHP.LN) Thursday said it expects good earnings growth this year as it posted a rise in first-quarter net income, in line with forecasts. </p> <p> Net income in the three months... Thu, 26 Apr 2012 08:09:37 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52160755&headline=shire-study-shows-vyvanse-has-promise-treating-binge-eating http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=52160755&headline=shire-study-shows-vyvanse-has-promise-treating-binge-eating <div class='newsbody'><p> By Sten Stovall </p> <p> Of DOW JONES NEWSWIRES </p> <p> LONDON -(Dow Jones)- U.K. drug maker Shire PLC (SHP.LN) Thursday said its drug for attention deficit hyperactivity disorder, Vyvanse, generated good results in a mid-stage clinical trial investigating its use in treating... Thu, 26 Apr 2012 06:53:19 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51984416&headline=shire-buying-pervasis-to-advance-regenerative-medicines-business http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51984416&headline=shire-buying-pervasis-to-advance-regenerative-medicines-business <div class='newsbody'><pre> By Sten Stovall Of DOW JONES NEWSWIRES </pre> <p> LONDON -(Dow Jones)- Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative... Thu, 12 Apr 2012 12:04:16 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51966136&headline=supernus-pharma-unveils-estimated-terms-of-ipo http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51966136&headline=supernus-pharma-unveils-estimated-terms-of-ipo <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Supernus Pharmaceuticals Inc. unveiled estimated terms of its planned initial public offering of 5.8 million shares to raise funds to bring its drug candidates to market. </p> <p> The drug developer, which focuses on treatments for diseases that... Wed, 11 Apr 2012 10:24:35 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51835922&headline=shire-top-line-results-of-the-prevent2-trial http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51835922&headline=shire-top-line-results-of-the-prevent2-trial <div class='newsbody'><p> LONDON -(Dow Jones)- Shire PLC (SHP.LN), global specialty biopharmaceutical company, Friday announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis. </p> <p> MAIN FACTS:... Fri, 30 Mar 2012 07:39:20 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51643891&headline=wsj-europes-stocks-finish-higher http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51643891&headline=wsj-europes-stocks-finish-higher <div class='newsbody'><pre> By Ishaq Siddiqi Of THE WALL STREET JOURNAL </pre> <p> European stocks finished higher Thursday, boosted by the continued run in strong economic indicators out of the U.S., improving sentiment about the health of the world's largest economy. </p> <p> The Stoxx Europe 600 index... Thu, 15 Mar 2012 15:10:22 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51638700&headline=uks-shire-to-expand-blood-drug-portfolio-with-us-biotech-buy http://www.advfn.com/nasdaq/StockNews.asp?stocknews=SHPGY&article=51638700&headline=uks-shire-to-expand-blood-drug-portfolio-with-us-biotech-buy <div class='newsbody'><pre> By Sten Stovall Of DOW JONES NEWSWIRES </pre> <p> LONDON -(Dow Jones)- U.K. drug maker Shire PLC (SHP.LN) Thursday said it is expanding its portfolio of blood disease therapies by buying FerroKin BioSciences, a closely held U.S. biotechnology firm, for up to $325 million... Thu, 15 Mar 2012 10:32:41 EDT